Apixaban with antiplatelet therapy after acute coronary syndrome.
By J. Alexander, R. Lopes, S. James, R. Kilaru, Yaohua He, Puneet Mohan, Deepak L. Bhatt, S. Goodman, F. Verheugt, M. Flather and 24 more. New England Journal of Medicine, 2011
910 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology
View Paper: https://www.semanticscholar.org/paper/870e5759fb5c57b54c55ba5643a21c05ab810cf2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Epidemiology
Citations in the corpus
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “Alexander 2011 (179) 21780946 Risk of events with Apixaban in ACS Multicenter prospective trial 7,392 Apixaban 3705 PC 3687 Median 6 d after ACS with significant risk factors: prior MI, DM, HF Planned PCI, ASA allergy, Significant HTN Bleeding diathesis Recent stroke Pericardial effusion Apixaban 5 ”